New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
07:38 EDTBMYBristol-Myers up 2.5% after better than expected Q4 results
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 29, 2015
05:23 EDTBMYBristol-Myers upgraded to Buy from Neutral at UBS
UBS analyst Marc Goodman upgraded Bristol-Myers Squibb to Buy saying Opdivo positions the company as a clear leader in the immuno-oncology space. Goodman raised his 2020 sales estimate for the drug to $10B from $8B citing the "very strong" renal cancer data, a larger lung market and additional smaller new indications. The recent pullback in the Pharma sector is overdone, Goodman tells investors in a research note on Bristol titled "We Like This Opportunity Right Here Right Now." He raised his price target for shares to $75 from $65. Bristol closed yesterday down $2.75 to $57.49.
September 28, 2015
15:20 EDTBMYBristol-Myers volatility at 52-week high
Subscribe for More Information
07:52 EDTBMYIIR Holdings to hold a conference
Subscribe for More Information
September 27, 2015
18:28 EDTBMYBristol-Myers reports longer term Phase 3 data on Opdivo for lung cancer
Subscribe for More Information
September 25, 2015
18:06 EDTBMYBristol-Myers says Opdivo demonstrates superior survival in Phase 3 trial
Subscribe for More Information
17:08 EDTBMYBristol-Myers' Opdivo approved by Health Canada for metastatic melanoma
Subscribe for More Information
16:17 EDTBMYBristol-Myers announces FDA filing update for Opdivo+Yervoy regimen
Subscribe for More Information
08:14 EDTBMYJPMorgan reiterates Overweight on Bristol-Myers after physician survey
Subscribe for More Information
08:02 EDTBMYBristol-Myers announces collaboration agreement with Moffitt Cancer Center
Bristol-Myers Squibb Company and Moffitt Cancer Center announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy. As part of the I-O RPM program, Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists.
07:22 EDTBMYEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
06:24 EDTBMYLeerink says AMAG 'extremely attractive' after McGuff label disclosure
Subscribe for More Information
September 23, 2015
05:31 EDTBMYBristol-Myers implied volatility of 40 at upper end of index mean range
Subscribe for More Information
September 22, 2015
08:09 EDTBMYBristol-Myers opportunity could be bigger than expected, says Morgan Stanley
Morgan Stanley analyst David Risinger said investors are overlooking Bristol-Myers kidney opportunity for Opdivo and believes expectations will rise. Risinger said investor perception is kidney cancer is a crowded market and question whether Opdivo can gernate significant sales. The analyst thinks upcoming data will refocus investors attention and that Opdivo can win meaningful market share in RCC. Risinger expects highly compelling survival data and bullish commentary on September 26 when CheckMate-025 details are presented at ESMO in Vienna.
07:43 EDTBMYDrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
06:19 EDTBMYClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
September 21, 2015
14:28 EDTBMYTuring CEO says will not change Daraprim price despite criticism
Subscribe for More Information
14:04 EDTBMYClinton vow to end drug price gouging sinks biotechs
Biotech stocks have declined across the board in afternoon trading following a tweet by Presidential candidate Hillary Clinton criticizing the "outrageous" prices of specialty drugs. TURING STEPS UP PRICING: Clinton's tweet directly referenced Turing Pharmaceuticals' Daraprim treatment for toxoplasmosis, which recently had its price hiked from just $13.50 per pill to $750 after the privately-held company acquired the drug from Impax Laboratories (IPXL). Importantly, Daraprim was first approved by the FDA in 1953 and its patents have long since expired. No generic versions of the drug currently exist, perhaps in part due to Turing executive chairman Martin Shkreli's strategy of tightly controlling distribution, according to a New York Post article on the issue. In a Bloomberg TV interview this morning, Shkreli claimed that the drug remains underpriced compared to what he called its peers in the rare disease space. However, note that a World Health Organization analysis from 2013 reported that over 190,000 cases of toxoplasmosis occur globally every year and Daraprim continues to be listed on the organization's list of essential medicines for a basic health-care system. INDUSTRY CRITICISM: Turing's Daraprim pricing prompted a response from the Infectious Diseases Society of America and the HIV Medicine Association, which criticized the "unjustifiable" new cost of the drug and urged a "rational" pricing strategy. The news surrounding Daraprim also comes on the heels of Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Hospira (HSP), in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. REPUBLICAN CONGRESS: In a research note released this afternoon, RBC Capital analyst Michael Yee reminded investors that Republicans still control Congress, offering a sobering reminder that campaign trail promises often fall by the wayside once the candidate steps into office. Yee explained that, though drug pricing debates during next year's election will probably generate headline risk for the biotech space, the Republican-controlled Congress is unlikely to sign into law any material changes on the issue. BIOTECH STOCK ACTION: Hillary Clinton's promise to "lay out a plan" tomorrow to tackle "price gouging" in the specialty drug market sent numerous biotech stocks plunging. Aerie Pharmaceuticals (AERI) has crashed 12.6% at time of writing, while Retrophin (RTRX), Ultragenyx (RARE), and PTC Therapeutics (PTCT) are down 14.7%, 13.4%, and 11%, respectively. Biotech giants AbbVie (ABBV), Gilead (GILD), Bristol-Myers Squibb (BMY) and Biogen (BIIB) have also slipped in intraday trading, while the NASDAQ Biotechnology index is down roughly 4%.
12:07 EDTBMYStocks with call strike movement; BABA BMY
Alibaba (BABA) January 75 call option implied volatility increased 8% to 34, Bristol-Myers (BMY) December 72.50 call option implied volatility decreased 5% to 30 according to iVolatility.
11:24 EDTBMYHillary Clinton vows to take on 'outrageous' specialty drug pricing
Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug called Daraprim which treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. The presidential nominee stated in a tweet, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." The iShares Nasdaq Biotechnology Index (IBB) moved lower following Clinton's tweet.
05:09 EDTBMYStocks with implied volatility movement; BMY SPLS
Stocks with implied volatility movement; Bristol-Myers (BMY) 39. Staples (SPLS) 50 according to iVolatility.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use